Logo

PharmaShots Weekly Snapshots (May 09-13, 2022)

Share this
PharmaShots Weekly Snapshots (May 09-13, 2022)

PharmaShots Weekly Snapshots (May 09-13, 2022)

Gedeon Richter’s Ryeqo (relugolix, estradiol, and norethindrone acetate) Receives NICE Recommendation for the Treatment of Women with Uterine Fibroids

Published: May 13, 2022 | Tags: Gedeon Richter, Ryeqo, relugolix, estradiol, norethindrone acetate, NICE, Uterine Fibroids

Neurocrine Biosciences’ Valbenazine Receives the US FDA’s Orphan Drug Designation for the Treatment of Chorea Associated with Huntington Disease

Published: May 13, 2022 | Tags: Neurocrine Biosciences, Valbenazine, US, FDA, Orphan Drug Designation, Chorea, Huntington Disease

AltruBio Reports the Completion of Patient Enrollment in P-I Clinical Study of Neihulizumab (ALTB-168) for Steroid-Refractory Acute Graft-Versus-Host Disease

Published: May 13, 2022 | Tags: AltruBio, P-I Clinical Study, Neihulizumab, ALTB-168, Steroid-Refractory, Acute Graft-Versus-Host Disease

Astex Reports Results of Decitabine and Cedazuridine (ASTX727 or DEC-C) in P-III (ASCERTAIN) Trial as Fixed-Dose Combination for Acute Myeloid Leukemia

Published: May 13, 2022 | Tags: Astex, Decitabine, Cedazuridine, ASTX727, DEC-C, P-III, ASCERTAIN Trial, Acute Myeloid Leukemia

Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery

Published: May 13, 2022 | Tags: Formosa, AimMax, CPN-301, P-III Trial, Inflammation, Pain, Cataract Surgery

Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer

Published: May 13, 2022 | Tags: Bridgebio, BMS, BBP-398, Cancer

BMS Presents Two-Year Results of Deucravacitinib in P-III (POETYK PSO) LTE Trial for the Treatment of Plaque Psoriasis at EADV 2022

Published: May 12, 2022 | Tags: BMS, Deucravacitinib, P-III, POETYK PSO LTE Trial, Plaque Psoriasis

Intercept Reports First Patient Dosing of Obeticholic Acid + Bezafibrate in the P-II Study for the Treatment of Primary Biliary Cholangitis

Published: May 12, 2022 | Tags: Intercept, Obeticholic Acid, Bezafibrate, P-II Study, Primary Biliary Cholangitis

Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer

Published: May 12, 2022 | Tags: Roche, Tecentriq, atezolizumab, Tiragolumab, P-III, SKYSCRAPER-01 Study, Non-Small Cell Lung Cancer

Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer

Published: May 12, 2022 | Tags: Taiho, Acquire, Cullinan, CLN-081, TAS6417, EGFR, Exon20, Non-Small Cell Lung Cancer

AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease

Published: May 12, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, U-ENDURE, Maintenance Study, Crohn's Disease

Acorda Therapeutics Entered into Distribution and Supply Agreements with Biopas to Commercialize Inbrija in Latin America for Parkinson's Disease

Published: May 12, 2022 | Tags: Acorda Therapeutics, Biopas, Inbrija, Parkinson's Disease

Lilly and Incyte's Olumiant (baricitinib) Receive the US FDA’s Approval for the Treatment of Hospitalized Patients with COVID-19

Published: May 11, 2022 | Tags: Lilly, Incyte, Olumiant, baricitinib, US, FDA, COVID-19

Visus Therapeutics Signs an Exclusive License Agreement with Zhaoke to Develop & Commercialize Brimochol PF and Carbachol PF for Presbyopia

Published: May 11, 2022 | Tags: Visus Therapeutics, Zhaoke, Brimochol PF, Carbachol PF, Presbyopia

UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Myasthenia Gravis at MGFA 2022

Published: May 11, 2022 | Tags: UCB, Zilucoplan, Rozanolixizumab, P-III, RAISE, MycarinG Study, Generalized Myasthenia Gravis, MGFA, 2022

Sanofi and AstraZeneca Report Results of Nirsevimab in P-III (MELODY) and P-IIb Trials for the Treatment of Respiratory Syncytial Virus

Published: May 11, 2022 | Tags: Sanofi, Nirsevimab, P-III, MELODY, P-IIb Trial, RSV

Cortexyme Entered into an Agreement to Acquire Novosteo for the Treatment of Rare Skeletal Diseases

Published: May 11, 2022 | Tags: Cortexyme, Acquire, Novosteo, Rare Skeletal Diseases

Evotec Expands 2018 Agreement with BMS for Targeted Protein Degradation Therapies

Published: May 11, 2022 | Tags: Evotec, 2018, BMS, Protein, Degradation Therapies

Pfizer to Acquire Biohaven for ~$11.6B

Published: May 10, 2022 | Tags: Pfizer, Acquire, Biohaven, ~$11.6B, Rimegepant, Zavegepant

Elpiscience Receives the US FDA’s IND Clearance of ES014 for the Treatment of Advanced Solid Tumors

Published: May 10, 2022 | Tags: Elpiscience, US, FDA, IND Clearance, ES014, Solid Tumors

BioArctic Partner Eisai Report the Completion of Rolling Submission of BLA to the US FDA for Lecanemab (BAN2401) to Treat Early Alzheimer's Disease

Published: May 10, 2022 | Tags: BioArctic, Eisai, Rolling Submission, BLA, US, FDA, Lecanemab, Alzheimer's Disease

Achilles Therapeutics Reports First Patient Dosing of Higher-Dose cNeT in P-I/IIa (CHIRON) Trial for the Treatment of Advanced Non-Small Cell Lung Cancer

Published: May 10, 2022 | Tags: Achilles Therapeutics, cNeT, P-I/IIa, CHIRON Trial, Non-Small Cell Lung Cancer

Monrol Partner Telix Report First Patient Dosing of TLX250 (177Lu-DOTA-girentuximab) in P-II (STARLITE 2) Study for Clear Cell Renal Cell Carcinoma

Published: May 10, 2022 | Tags: Monrol, Telix, TLX250, 177Lu-DOTA-girentuximab, P-II, STARLITE 2 Study, Clear Cell Renal Cell Carcinoma

Mereo BioPharma Reports Results of Alvelestat in P-II (ASTRAEUS) Trial for Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Published: May 10, 2022 | Tags: Mereo BioPharma, Alvelestat, P-II, ASTRAEUS Trial, Alpha-1 Antitrypsin Deficiency, Emphysema

Twist Bioscience Enters into Multiple Agreement with Astellas to Identify Antibodies & Reduce Tumor Microenvironment-Mediated Immunosuppression

Published: May 9, 2022 | Tags: Twist Bioscience, Astellas, Antibodies, CAR Cell Therapy Technology

The US FDA Extends Review Period of Myfembree’s sNDA to Treat Moderate to Severe Pain Associated with Endometriosis

Published: May 9, 2022 | Tags: US, FDA, Myfembree, sNDA, Pain, Endometriosis

Oxurion Reports Results of THR-687 in Part A of P-II (INTEGRAL) Trial for the Treatment of Diabetic Macular Edema

Published: May 9, 2022 | Tags: Oxurion, THR-687, Part A, P-II, INTEGRAL Trial, Diabetic Macular Edema

Elpiscience Partner Compass Report Interim Results of ES104 + Paclitaxel in P-II Study for the Treatment of Biliary Tract Cancers

Published: May 9, 2022 | Tags: Elpiscience, Compass, ES104, Paclitaxel, P-II, Study, Biliary Tract Cancers

Nykode Reports Interim Results of VB10.16 in P-II (VB C-02) Trial for the Treatment of Advanced Cervical Cancer

Published: May 9, 2022 | Tags: Nykode, VB10.16, P-II, VB C-02 Trial, Cervical Cancer

Evofem Presents Results of Phexxi in P-III (AMPOWER) Clinical Trial for the Prevention of Pregnancy at ACOG 2022

Published: May 9, 2022 | Tags: Evofem, Phexxi, P-III, AMPOWER, Clinical Trial, Urinary Tract Infections, ACOG, 2022

Related Post: PharmaShots Weekly Snapshots (May 02-06, 2022)


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions